<DOC>
	<DOCNO>NCT01014156</DOCNO>
	<brief_summary>You admit hospital pulmonary embolism . You treat anticoagulant . The investigator know , despite treatment , pulmonary embolism threat especially heart function compromized . The investigator investigate well know study drug ( epoprostenol ) top regular treatment anticoagulant , see heart function optimize</brief_summary>
	<brief_title>Epoprostenol Pulmonary Embolism</brief_title>
	<detailed_description>Pulmonary thromboembolism ( PE ) circulatory and/or respiratory symptom associate high morbidity mortality . Acute pulmonary hypertension hallmark severe PE , hold responsible full spectrum clinical manifestation complication . Although common belief mechanical obstruction thrombus mass cause pulmonary hypertension , strong evidence indicate pulmonary vasoconstriction contribute significantly rise pulmonary vascular resistance . Although patient receive anticoagulant treatment immediately diagnosis establish , morbidity mortality still disturbingly high circulatory and/or respiratory symptom accompany PE , hemodynamically stable PE patient echocardiographic sign acute right ventricle overload . There generally accept guideline additional treatment option patient moderate-to-severe PE . Thrombolytic therapy recommend many hemodynamic symptom severe , effectiveness never proven control trial . In patient moderate-to-large PE associate echocardiographic sign right ventricle overload , still circulatory stable , mortality increase , thrombolytic therapy appear beneficial . Given plausible role pulmonary vasoconstriction pathogenesis PE associate pulmonary hypertension , potential benefit pulmonary vasodilator important.There experimental evidence antagonise pulmonary vasoconstriction administration selective vasodilator may beneficial animal PE . In addition , anecdotal evidence similar kind exists human acute PE . We hypothesise PE patient echocardiographic evidence acute right ventricle overload , epoprostenol sodium ( FlolanÂ® ) result partial complete reversal echocardiographic abnormality , well improvement respiratory circulatory symptom sign .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>acute ( symptoms &lt; 24 hr ) right ventricular dilatation ( &gt; 30 mm end diastolic , systolic PAP &gt; 50 mmHg , absence right ventricular wall hypertrophy ) age 18 year 70 year body mass index &gt; 35 kg/m2 duration symptom &gt; 24 hour ( since onset acute increase symptom ) severe circulatory shock ( systemic blood pressure systolic &lt; 80 mmHg , diastolic blood pressure &lt; 45 mmHg ) respiratory failure , require mechanical ventilation . patient , opinion supervise physician , require thrombolytic therapy . severe preexistent cardiopulmonary disease ( heart failure , obstructive pulmonary disease , emphysema ) atrial fibrillation refusal inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>pulmonary embolism</keyword>
	<keyword>vasoconstriction</keyword>
	<keyword>right ventricular dysfunction</keyword>
	<keyword>epoprostenol</keyword>
	<keyword>acute pulmonary embolism right ventricular dysfunction</keyword>
</DOC>